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Abstract
Background: Mycobacterium leprae is the only pathogenic bacteria able to infect peripheral nerves. Neural
impairment results in a set of sensitive, motor and autonomic disturbances, with ulcers originating primarily on the
hands and feet. The study objectives were to analyze the clinic-epidemiological characteristics of patients attended
at one specialized dressing service from a leprosy-endemic region of the Brazilian Amazon and to evaluate the
effect of low level laser therapy (LLLT) on wound healing of these patients.
Methods: Clinic-epidemiological evaluation of patients with leprosy sequelae was performed at the reference unit
in sanitary dermatology of the state of Pará in Brazil. We conducted anamnesis, identification of the regions
affected by the lesions and measurement of ulcer depth and surface area. After that, we performed a randomized
clinical trial. Fifty-one patients with ulcers related to leprosy were evaluated, twenty-five of them were randomly
assigned to a low level laser therapy group or a control group. Patients were treated 3 times per week for 12
weeks. Outcome measures were ulcer surface area, ulcer depth and the pressure ulcer scale for healing score
(PUSH).
Results: Ninety-seven ulcers were identified, with a mean (SD) duration of 97.6 (111.7) months, surface area of 7.3
(11.5) cm
2, and depth of 6.0 (6.2) mm. Statistical analysis of the data determined that there were no significant
differences in the variables analyzed before and after treatment with low level laser therapy.
Conclusions: Ulcers in patients with leprosy remain a major source of economic and social losses, even many
years after they have been cured of M. leprae infection. Our results indicate that it is necessary to develop new and
more effective therapeutic tools, as low level laser therapy did not demonstrate any additional benefits to ulcer
healing with the parameters used in this study.
Trial Registration: The trial was registered at ClinicalTrials.gov as NCT00860717.
Background
Leprosy is a chronic infectious disease caused by Myco-
bacterium leprae, the only pathogenic bacteria able to
infect peripheral nerves. About 30% of people with
leprosy develop nerve damage. Neural impairment
results in a set of sensitive, motor and autonomic distur-
bances, with ulcers originating primarily on the hands
and feet. Neuropathic ulcers are one of the most com-
mon sequelae of leprosy, but little is known about their
clinical and epidemiological aspects. They are very dis-
abling to the patient and can result in deformity and/or
amputation of the affected limb [1,2].
Brazil has the highest prevalence of leprosy cases in the
world (3.21 cases per 10000 inhabitants in 2007), with
the majority of these cases registered in the North and
Middle-West Regions [3]. The State of Pará, in the Ama-
zon region, registered 4955 new leprosy cases in 2006,
accounting for nearly 1% of all cases world-wide [4].
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1 or 2 disability. In 2005, the cure rate for leprosy was
71%, which was a questionable result according to Brazi-
lian Health Ministry [5,6]. Delayed diagnostics, lack of
appropriate treatment and failure in leprosy reactions
control contribute to the occurrence of nerve damage
and neuropathic ulcers in these patients.
Different methods of treatment have been used in ulcer
management, but the outcomes are frequently dissatisfac-
tory, and many people must live with chronic wounds
that result in high economic and social costs [2].
Low level laser therapy (LLLT) has been used to accel-
erate wound healing since the late 1960 s, but its results
are controversial [7]. One study [8] evaluated the use of
LLLT in the treatment of leprosy ulcers with satisfactory
results (66% were cured). However, in a systematic
review published by Cochrane [9], the authors did not
find evidence of wound healing improvement related to
LLLT.
The main objectives of this study were to analyze clin-
ical and epidemiological characteristics of patients with
leprosy ulcers and to evaluate the effect of LLLT on
wound healing in these patients.
Methods
This study was approved by the Center of Tropical
Medicine Research Ethics Committee from the Federal
University of Pará (protocol number 074/2006 - CEP/
NMT). The trial was registered at ClinicalTrials.gov as
NCT00860717.
Setting and Participants
The present study was done at the dressing service of
Dr. Marcello Candia Reference Unit in Sanitary Derma-
tology of the State of Pará in Brazil (UREMC), and was
carried out from January 2007 to January 2008. Partici-
pating subjects met the following inclusion criteria: (1)
presented with neuropathic ulcer; (2) attended at least 3
weekly appointments at the dressing service of UREMC;
(3) completed specific multi-drug therapy for M. leprae;
and (4) gave written informed consent to participate in
the study. There were no restrictions on gender, race or
age-group, or the duration of ulcers. Subjects with the
following conditions were not allowed to participate or
were excluded from the study: (1) clinically detectable
infection in the ulcer; (2) use of drugs, like corticoster-
oids that could interfere with the wound healing pro-
cess; (3) use of special dressings like hydrocolloid,
calcium alginate, activated carbon or any kind of thera-
peutic procedure different from that used routinely for
both groups of study; (4) non-attendance to therapeutic
program (six sequential times or nine intercalated); (5)
pregnancy; and (6) discomfort during treatment
procedure.
Clinical and epidemiological evaluation of patients
with leprosy attended at the dressing service of UREMC
were performed before the beginning of the randomized
clinical trial. We conducted anamnesis, identification of
the regions affected by the lesions (including a photo-
graphic register) and measurement of ulcer depth and
surface area. The area was measured using UTHSCSA
ImageTool 3.0 software (University of Texas Health
Science Center, San Antonio, USA).
Randomization and Interventions
Patients selection was performed after examination of all
subjects who attended the dressing service from January
to March, 2007. After initial assessment, subjects were
randomly allocated into two groups of study, a control
group (CG) and an experimental group (EG). Sample
size was determined by the total number of patients
that met the inclusion criteria and agreed to participate
in this study. The randomization schedule was generated
using BioEstat 5.0 software (Sociedade Civil Mamirauá,
Amazonas, Brazil) after inclusion criteria had been eval-
uated and was done by random sampling. The subjects
received a code related to the order in which they were
evaluated. After all participants were recruited, they
were allocated to the CG or the EG according to a
sequence generated by the BioEstat 5.0 software. All
stages of the randomization process were performed by
the same researcher (JGB).
Subjects from the CG received routine treatment,
including daily simple dressings with sterile gauze after
wound cleaning with a 0.9% physiologic solution, use of
1% hydrophilic silver sulfadiazine cream (Prati Dona-
duzzi Laboratory, Paraná, Brazil) and orientation about
the use of adapted footwear, self-care and the preven-
tion of disabilities. Surgical debridement was done
whenever indicated by nursing or orthopedic services
from UREMC. Subjects from the EG received LLLT
3 times per week for 12 weeks, in addition to the same
treatment as patients from the CG.
The LLLT equipment was a TWIN LASER
(MM Optics, São Paulo, Brazil), an indium-gallium-
aluminnium-phosphide (InGaAlP) semiconductor laser
with a maximum output power of 40 mW, continuous
radiation emission of visible red light with 660 nm
wavelength (+/- 10 nm) and a spot area of 0.04 cm
2.
T h ee n e r g yd e n s i t yu s e dw a s4Jp e rp o i n ti nt h e
wound edges and 2 J/cm
2 in the wound bed with a
power density of 1 W/cm
2.
Wound beds were irradiated using a scanning techni-
que with no direct contact. The laser probe was held
upright to the ulcer during the treatment session and
kept 1 cm away from the target tissue. Wound edges
were treated using a “spot# technique, 1 cm from its
border. Irradiated points on the wound edge were
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was used in these sites by holding the laser probe
upright to the ulcer edge. Direct skin contact was pre-
vented by fixing a piece of transparent and disposable
polyvinyl chloride (PVC) to the laser probe. The area of
each ulcer was determined and the intended energy
density for the time of the treatment session was calcu-
lated using the following equation: T = D × A/P, where
(T) is time in seconds, (D) is energy density in J/cm
2,
(A) is bed ulcer area in cm
2 and (P) is the irradiance
power in Watts.
All subjects included in this trial were evaluated
biweekly until the end of the 12 weeks treatment period
or until complete cicatrization of the treated ulcer. The
last assessment was done one week after the last treat-
ment session. The laser device used in this trial emitted
red visible light and thus limited our ability to blind
patients, as they could see the irradiation even when
protective spectacles were used. In order to avoid dupli-
city in treatment technique and assessment interpreta-
tion, all LLLT and ulcer evaluation procedures were
performed by one researcher (JGB).
Outcomes
U l c e ra r e a ,d e p t ha n dp r e s s u r eu l c e rs c a l ef o rh e a l i n g
tool score (PUSH) were investigated in the clinical trial.
Digital photographs were taken to evaluate ulcer area
and analyzed using UTHSCSA ImageTool 3.0 software.
To evaluate ulcer depth, a sterilized pincer was gently
introduced into the bottom of the deepest region of the
ulcer and measured from the tip to the surface of the
skin. The PUSH tool score was submitted to a cross-
cultural adaptation to the Portuguese language [10] and
it resulted in the following sub-scores: surface area, exu-
date amount and type of wound tissue. This score ran-
ged from 0 to 17, where 0 indicated a healed wound
and 17 indicated an ulcer of more than 24 cm
2 of sur-
face area, with a heavy amount of exudate and the pre-
sence of necrotic tissue.
Statistical analysis
The collected data were submitted to descriptive analy-
sis and methods of statistical inference using BioEstat
5.0 software. Statistical significance was assessed using
a significance level of 0.05. The Student’s t test was
used to assess quantitative data of related samples,
before and after treatment, and quantitative data of
independent samples (CG and EG). The Wilcoxon test
and the Mann-Whitney test were used to assess ordi-
nal data of related and independent samples, respec-
tively. The Fisher’s exact test was used to assess the
gender proportion and the use of adapted footwear
between CG and EG, as well as the ulcer localization
in different groups. The Z test was used to assess the
surface area and depth of plantar ulcers compared to
those on the legs or ankles.
Results
Clinical and epidemiological study
A total of 51 patients, with a mean age of 59.9 years old
(minimum of 17 and maximum of 82), were evaluated
in the early clinical and epidemiological study. Forty
subjects (78%) were male and eleven (22%) were female.
Leprosy was diagnosed an average of 27.6 years ago
(SD= 18.7) and patients were cured of M. leprae infec-
tion 11.6 years ago (SD= 6.3). The most common clini-
cal form was lepromatous leprosy, which corresponded
to 72% of all cases.
Ninety-seven ulcers were identified on the evaluated
patients. On average, ulcer duration was 97.6 months
(SD= 111.7), surface area was 7.3 cm
2 (SD= 11.5) and
depth was 6.0 mm (SD= 6.2). The majority of the ulcers
(53%) was located on the plantar region of the foot and
were primarily distributed on those areas that bear
weight while walking and standing, especially at the
metatarsals head area, the fifth metatarsal bone and cal-
caneus area (Figure 1). Forty ulcers (41%) were located
on legs and ankles and six lesions (6%) were located on
hands and dorsal face of the feet. Different types of
lesions were found, varying from blisters and fissures to
extensive ulcers with secondary infestation, like myiasis
(Figure 2). Besides, ten patients had a fibrotic skin sur-
rounding the ulcers, four had fibrosis with lymphedema,
and one presented only lymphedema. A striking differ-
ence was observed in area and depth between ulcers
found on the plantar region (area: 4.2 cm
2, depth: 7.2
mm) and ulcers on legs or ankles (area 13.2 cm
2, depth:
4.0 mm) (Table 1).
There was a large number of lesions on the legs and
ankles of patients, but they were especially prevalent
among those who were more than 40 years old. The
data indicate that ulcer location is inverted between
patients less than 40 years old and those over 40.
Only 18% of ulcers from younger patients were
located on legs or ankles, while 46% of ulcers from
patients over 40 years old were on the legs or ankles
(Table 2).
There were 13 cases (25%) of systemic high blood
pressure (HBP), making it the most frequent comorbid-
ity. The anatomic distribution of ulcers in patients with
HBP assumed peculiar characteristics, as they located
preferentially on the legs or ankles, when compared to
subjects without HBP (Table 2).
Patients have an average of 3.4 simple dressings per
week at the dressing service of UREMC, resulting in an
estimated expenditure of $100.000 USD per year on dis-
posable dressing material alone. Despite the availability
o fac o m p l e t eo r t h o p e d i cw o r k s h o pt h a tm a k e sm a n y
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44% of evaluated patients did not use adapted footwear
or an equivalent.
Clinical trial
Of the 51 patients evaluated at the beginning of the
trial, 25 were randomly allocated into the two trial
groups (Figure 3). During the study follow-up, two sub-
jects from the EG left the trial. One subject exceeded
the protocol absence limit due to family problems and
the other subject asked to drop out after 14 irregular
sessions of LLLT, as he did not perceive any improve-
ment in his ulcers. Subject demographics and baseline
clinical characteristics that were included in the statisti-
cal analysis are described in Table 3. The data demon-
strate that the CG and the EG were homogenous at the
start of the clinical trial.
The surface areas, depths and PUSH scores of the
ulcers of patients in both study groups, both before and
after the treatment period, are recorded in Table 4. The
data indicate that there were no statistical differences in
any of the investigated variables, including the subscores
for exudate amount and type of wound tissue. No treat-
ment-related adverse effects were reported during this
study.
Discussion
Ulcers in patients with leprosy can remain for several
years after the initial infection is resolved and can result
in large economic and social losses. Such losses were
observed in this study, which was primarily composed
of former patients that have lived with their ulcers for
many years. The most important causal factor for neu-
ropathic foot ulcers is the presence of a dynamic or sta-
tic deformity leading to local areas of peak pressure on
insensitive skin, which has been well illustrated by pres-
sure studies [11]. This repetitive overload on specific
areas of the sole could partially explain why plantar
ulcers are deeper and smaller than leg and ankle ulcers.
Almost half of the evaluated subjects in this study did
not use any kind of adapted footwear, suggesting some
negligence by the patients in the prevention of disabil-
ities and self-care procedures. The free distribution of
special footwear doesn’t ensure its adequate utilization.
Health care workers need to be constantly pushed to
establish a patient continuum education process about
self-care routines and to improve the techniques cur-
rently employed to encourage the use of preventive
tools. Low adherence to such programs and self-care
procedures is a concern of countries that still bear a sig-
nificant leprosy burden.
Figure 1 Anatomic distribution of the ulcers on the plantar region. Of 51 plantar ulcers, 33 were on right feet and 18 were on left feet.
Ulcers were more common on the areas of the sole that bear weight during walking and standing. The little black circles indicate isolated
lesions that were not included in the pictured percentages.
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nantly chronic wounds, which could have interfered
with LLLT success. Fibroblasts in chronic wounds have
impaired responsiveness to growth hormone, which may
be due to an increased number of senescent cells [12].
It was observed in neuropathic diabetic foot ulcers that
wound duration negatively affected the chance of
healing after 12 weeks of proper wound care [13]. A
high prevalence of vasomotor reflex impairment attribu-
ted to autonomic nerve lesions has been observed in
newly diagnosed patients with leprosy [14]. Lepromatous
patients exhibit a tendency to develop chronic leg ulcers,
which are partially caused by a single vascular distur-
bance during M. leprae infection and/or by peripheral
Figure 2 Examples of ulcers in patients with leprosy. (A) Blister formed after walking long distances that later became an ulcer. (B) Fissure
on the base of the second toe of the right foot. (C) Right medial malleolus ulcer from a patient with leprosy and HBP. (D) Plantar ulcer on the
region of second metatarsal head. (E) Myiasis in a chronic leg ulcer. (F) Chronic ulcer on a lower limb stump.
Table 1 Ulcer area and depth according to location
a
Localization Number of ulcers Area (cm
2) Depth (mm)
Plantar 51 4.2 (6.2) 7.2 (7.5)
Legs/Ankles 40 13.2 (15.7) 4.0 (1.4)
Mean difference between groups (95% CI) -9.23 (-9.35 to -9.11) 3.10 (3.06 to 3.15)
p value <.001* <.01*
aValues are means (SDs) unless otherwise indicated. CI = confidence interval
*As determined by the Z test for two independent samples.
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b l eo c c u r r e n c eo fc h r o n i cl e ga n da n k l eu l c e r si nt h i s
sample, especially in subjects who were hypertensive or
over 40 years old. One study of 124 patients with leg
wounds of different etiologies identified that 54% of
them were hypertensive [16]. It is necessary to give
Table 2 Ulcer occurrence and location by age-group and
on patients with and without high blood pressure (HBP)
Subjects Number of
ulcers
Plantar Legs and
ankles
Other
sites
≤ 40 years (n = 13) 17 13
(76%)
3 (18%) 1 (6%)
> 40 years (n = 38) 80 38
(48%)
37 (46%) 5 (6%)
p value
a .02 .02 .71
With HBP (n = 13) 40 14
(35%)
22 (55%) 4 (10%)
Without HBP (n = 38) 57 37
(65%)
18 (32%) 2 (3%)
p value
a <.01 .01 .18
aAs determined by Fisher’s exact test.
Figure 3 Flow of participants through the trial.
Table 3 Demographics and baseline characteristics by
treatment group
1
Clinical data Control
group
Experimental
group
p
value
Gender (male/female) 9/3 9/2 1.0
a
Age, years 58.5 (19.2) 53.3 (15.2) .42
b
Most common clinical form (%) LL
# (92%) LL
# (73%) .31
a
Years since leprosy diagnostic 38.4 (16.0) 39.1 (15.7) .91
b
Years free of M. leprae 14.2 (5.6) 14.3 (3.9) .97
b
Ulcers duration (months) 71.7 (82.2) 123.3 (159.6) .28
b
Ulcers area 5.3 (9.2) 4.2 (5.9) .70
b
Ulcers depth 6.3 (5.4) 6.2 (5.1) .96
b
PUSH score 9.7 (3.4) 9.6 (3.3) .96
c
Adapted footwear usage 5 subjects 4 subjects 1.0
a
1Values are means (SDs) unless otherwise indicated.
# LL = Lepromatous
leprosy.
a As determined by Fisher’s exact test.
bAs determined by an independent 2-sample t test.
cAs determined by the Mann-Whitney U test.
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as this comorbidity was common in our study and has
the potential to negatively affect the wound healing pro-
cess in patients with leprosy. The follow-up period of 12
w e e k si sl o n g e rt h a ns o m ep r e v i o u ss t u d i e s[ 8 , 1 7 - 1 9 ] ,
but was chosen because it is enough time for the wound
healing process to complete [20-22].
Rest is a common recommendation as a strategy of
s e l f - c a r e ,b u ti tw a sn o ta d o p t e db yt h em a j o r i t yo f
patients. Such behavior combined with the non-use
of adapted footwear (though use was advised by the
health care staff) could have interfered with the results,
as the plantar ulcers remained under mechanic stress
during daily living activities and walking. The fact that
researchers were not blind in the study and therefore
knew which group subjects were receiving laser therapy
or routine treatment could have led to a possible bias,
but the photographic register of all treated ulcers allows
confirmation of collected and analyzed data.
There was no formally sample size calculation, but we
included all subjects attended at dressing service of
UREMC that met the inclusion criteria. The small sam-
ple size of this clinical trial limits the application of the
data in other settings or studies, and does not provide
robust evidence of no effect of laser in these wounds.
More studies with larger sample sizes are necessary and
should include different research institutes and
universities, as well as additional control over self-care
and prevention of disabilities procedures.
Even though the supporting evidence is weak, LLLT
has been used by health care professionals in many
countries around the world for the treatment of venous,
pressure and diabetic chronic wounds [23]. Our results
disagree with those obtained by one previous study [8],
where a wound cure rate of 66% was reached. However,
that study was greatly limited as the authors included
only four patients (12 ulcers) and had no control group.
Many in vitro, in vivo and human studies report positive
effects of LLLT [24-33], though there are other works
that did not reach the same conclusion [34-41]. One
systematic review of papers published after 1999 [42]
concluded that there is no sufficient scientific evidence
to support the use of LLLT for wound healing. The
author declares that new controlled studies are neces-
sary to determine its real efficacy and to delimitate
more adequate procedures for each group of patients.
Although their focus was on a different primary dis-
ease, our results are in accordance with a systematic
review by Flemming and Cullum published by Cochrane
Library [9]. They found no evidence that treatment with
LLLT could provide any benefit for venous leg ulcer
healing. However, in one meta-analysis [43], the authors
concluded that LLLT is an effective tool to promote
wound healing. These conflicting results may be
Table 4 Results of Analysis Comparing Outcomes: Evaluation Within Groups and Between Treatment Groups
a
Outcome measure Control group (n = 12) Experimental group (n = 11) Mean difference between groups (95% CI) p value
d
Area (cm
2)
Baseline 5.3 (9.2) 4.2 (5.9) -1.08 (-6.93 to 4.75) .70
After intervention 4.4 (8.5) 3.8 (5.7) -0.63 (-6.10 to 4.84) .81
Mean difference
in change scores
(95% CI)
0.82 (0.00 to 1.66) 0.37 (-0.77 to 1.51)
p value
c .05 .49
Depth (mm)
Baseline 6.3 (5.4) 6.2 (5.1) -0.08 (-4.07 to 3.90) .96
After intervention 5.4 (5.7) 4.1 (3.9) -1.29 (-5.00 to 2.41) .47
Mean difference
in change scores
(95% CI)
0.85 (-0.40 to 2.11) 2.0 (-0.60 to 4.74)
p value
c .16 .11
PUSH score
b
Baseline 9.7 (3.4) 9.6 (3.3) .96
e
After intervention 8.4 (5.3) 7.9 (5.3) .93
e
p value
e .09 .24
aValues are means (SDs) unless otherwise indicated. CI = confidence interval.
b PUSH = Pressure Ulcer Scale for Healing (ranged from 0 to 17, where 0 indicated a healed wound and 17 indicated an ulcer greater than 24 cm
2 in surface
area, with a heavy amount of exudate and the presence of necrotic tissue).
cAs determined by a dependent sample t test.
dAs determined by an independent 2-sample t test.
eAs determined by the Mann-Whitney U test.
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ing different laser types, variance of treatment para-
meters and selected samples. The evaluated papers
reported no side effects related to exposure to LLLT.
Management of chronic ulcers in patients with leprosy
includes different types of dressings, orthopedic and
plastic surgeries, plaster casts, special footwear, splints,
crutches, wheelchair use and absolute rest. Despite this,
clinical experience shows that patient compliance to the
therapeutic procedures is a key consideration in treat-
ment choice and that without patient collaboration the
result of the treatment can be frustrating. Low patient
adherence to rehabilitation and prevention of disabilities
programs (e.g. usage of appropriate footwear) indicate
that more research and educational measures are neces-
sary to improve the adoption of such strategies. More
research is also needed to develop more efficient thera-
peutic tools.
Conclusions
Ulcers in patients with leprosy sequelae remain a major
source of economic and social losses, even many years
after they have been cured of M. leprae infection. With
the parameters used in this study, low level laser therapy
did not demonstrate any additional benefit to ulcer heal-
ing for these patients, when compared to patients in the
control group.
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